[144] Zimmer Biomet Holdings, Inc. SEC Filing
Zimmer Biomet reports a proposed sale of 7,500 common shares through Fidelity Brokerage on the NYSE, with an aggregate market value of $766,708.20, scheduled for 08/13/2025. The filing lists 198,095,984 shares outstanding and shows the securities to be sold were acquired through employee programs: small ESPP purchases on 12/29/2023 (25), 06/28/2024 (28) and 12/31/2024 (29), and restricted stock vesting on 02/18/2025 (5,911) and 02/20/2025 (1,507). The filer reports Nothing to Report for sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Zimmer Biomet segnala una proposta di vendita di 7,500 azioni ordinarie tramite Fidelity Brokerage sul NYSE, per un valore di mercato complessivo di $766,708.20, prevista per il 08/13/2025. Il documento riporta 198,095,984 azioni in circolazione e specifica che i titoli da vendere sono stati acquisiti tramite programmi per dipendenti: piccoli acquisti ESPP il 12/29/2023 (25), 06/28/2024 (28) e 12/31/2024 (29), e vesting di azioni soggette a restrizioni il 02/18/2025 (5,911) e il 02/20/2025 (1,507). Il dichiarante indica Nulla da segnalare per vendite nei precedenti tre mesi e include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali negative non divulgate.
Zimmer Biomet informa una propuesta de venta de 7,500 acciones ordinarias a trav茅s de Fidelity Brokerage en el NYSE, por un valor de mercado total de $766,708.20, programada para el 08/13/2025. El expediente indica 198,095,984 acciones en circulaci贸n y muestra que los t铆tulos a vender se adquirieron mediante programas para empleados: peque帽as compras ESPP el 12/29/2023 (25), 06/28/2024 (28) y 12/31/2024 (29), y vesting de acciones restringidas el 02/18/2025 (5,911) y el 02/20/2025 (1,507). El declarante informa Nada que reportar sobre ventas en los 煤ltimos tres meses e incluye la representaci贸n habitual de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada.
Zimmer Biomet电� NYSE鞐愳劀 Fidelity Brokerage毳� 韱淀暣 7,500 氤错喌欤茧ゼ 齑� 鞁滉皜 $766,708.20搿� 毵り皝頃� 鞓堨爼鞚措澕瓿� 氤搓碃頄堨溂氅�, 鞚检爼鞚� 08/13/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐惖鐢 198,095,984欤缄皜 氚滍枆欤检嫕靾橂 旮办灛霅橃柎 鞛堦碃, 毵る弰霅� 歃濌秾鞚� 歆侅洂 頂勲攴鸽灗鞚� 韱淀暣 旆摑霅� 瓴冹溂搿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟: ESPP 靻岇暋 毵れ垬 12/29/2023(25), 06/28/2024(28), 12/31/2024(29) 氚� 鞝滍暅欤� 氩犾姢韺� 02/18/2025(5,911)瓿� 02/20/2025(1,507). 鞝滌稖鞛惖鐢 斓滉芳 3臧滌洈臧勳潣 毵る弰鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚措澕瓿� 氤搓碃頄堨溂氅�, 韺愲Г鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟电� 響滌 歆勳垹鞚� 韽暔頄堨姷雼堧嫟.
Zimmer Biomet signale la cession propos茅e de 7,500 actions ordinaires via Fidelity Brokerage sur le NYSE, pour une valeur marchande totale de $766,708.20, pr茅vue le 08/13/2025. Le d茅p么t indique 198,095,984 actions en circulation et pr茅cise que les titres 脿 vendre ont 茅t茅 acquis par des programmes employ茅s : petits achats ESPP le 12/29/2023 (25), 06/28/2024 (28) et 12/31/2024 (29), et lev茅es de restrictions (vesting) d'actions restreintes le 02/18/2025 (5,911) et le 02/20/2025 (1,507). Le d茅clarant indique Rien 脿 signaler concernant des ventes au cours des trois derniers mois et inclut la d茅claration standard selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Zimmer Biomet meldet einen vorgeschlagenen Verkauf von 7,500 Stammaktien 眉ber Fidelity Brokerage an der NYSE mit einem Gesamtmarktwert von $766,708.20, geplant f眉r den 08/13/2025. Die Einreichung nennt 198,095,984 ausstehende Aktien und weist aus, dass die zu verkaufenden Wertpapiere durch Mitarbeiterprogramme erworben wurden: kleine ESPP-K盲ufe am 12/29/2023 (25), 06/28/2024 (28) und 12/31/2024 (29) sowie Vesting von Restricted Stock am 02/18/2025 (5,911) und 02/20/2025 (1,507). Der Meldende gibt f眉r Verk盲ufe in den letzten drei Monaten Nichts zu melden an und f眉gt die 眉bliche Erkl盲rung hinzu, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Clear disclosure of proposed sale quantity (7,500 shares) and aggregate market value ($766,708.20)
- Source of shares documented: ESPP purchases and restricted stock vesting with specific acquisition dates and amounts
- No sales reported in the prior three months ("Nothing to Report"), indicating this filing records a discrete proposed sale
- None.
Insights
TL;DR: Proposed sale appears to be a routine, compensation-linked disposition with limited market impact based on the disclosed size and sourcing.
The filer plans to offer 7,500 shares via Fidelity with an aggregate market value shown as $766,708.20. The detailed acquisition lines identify the shares as coming from an ESPP and recent restricted stock vesting, indicating these are compensation-related holdings rather than an outright purchase from a third party. The form also reports no securities sold in the prior three months, which suggests this filing documents a discrete proposed sale. From an investor-analysis perspective, the disclosure is transparent and provides clear traceability of the lot origins, but the filing does not identify the seller by name within the provided content.
TL;DR: Filing follows Rule 144 disclosure format and includes the standard attestation about material nonpublic information and trading-plan references.
The notice contains the customary representation that the person for whose account the securities will be sold does not know of material adverse information not publicly disclosed, and it references trading-plan adoption language where applicable. The broker is identified as Fidelity Brokerage Services LLC and the intended exchange is the NYSE. The filing records the dates and nature of acquisition (ESPP purchases and restricted stock vesting), which supports compliance with Rule 144 requirements on provenance of shares. There is no material adverse disclosure or indication of regulatory issues in the provided content.
Zimmer Biomet segnala una proposta di vendita di 7,500 azioni ordinarie tramite Fidelity Brokerage sul NYSE, per un valore di mercato complessivo di $766,708.20, prevista per il 08/13/2025. Il documento riporta 198,095,984 azioni in circolazione e specifica che i titoli da vendere sono stati acquisiti tramite programmi per dipendenti: piccoli acquisti ESPP il 12/29/2023 (25), 06/28/2024 (28) e 12/31/2024 (29), e vesting di azioni soggette a restrizioni il 02/18/2025 (5,911) e il 02/20/2025 (1,507). Il dichiarante indica Nulla da segnalare per vendite nei precedenti tre mesi e include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali negative non divulgate.
Zimmer Biomet informa una propuesta de venta de 7,500 acciones ordinarias a trav茅s de Fidelity Brokerage en el NYSE, por un valor de mercado total de $766,708.20, programada para el 08/13/2025. El expediente indica 198,095,984 acciones en circulaci贸n y muestra que los t铆tulos a vender se adquirieron mediante programas para empleados: peque帽as compras ESPP el 12/29/2023 (25), 06/28/2024 (28) y 12/31/2024 (29), y vesting de acciones restringidas el 02/18/2025 (5,911) y el 02/20/2025 (1,507). El declarante informa Nada que reportar sobre ventas en los 煤ltimos tres meses e incluye la representaci贸n habitual de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada.
Zimmer Biomet电� NYSE鞐愳劀 Fidelity Brokerage毳� 韱淀暣 7,500 氤错喌欤茧ゼ 齑� 鞁滉皜 $766,708.20搿� 毵り皝頃� 鞓堨爼鞚措澕瓿� 氤搓碃頄堨溂氅�, 鞚检爼鞚� 08/13/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐惖鐢 198,095,984欤缄皜 氚滍枆欤检嫕靾橂 旮办灛霅橃柎 鞛堦碃, 毵る弰霅� 歃濌秾鞚� 歆侅洂 頂勲攴鸽灗鞚� 韱淀暣 旆摑霅� 瓴冹溂搿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟: ESPP 靻岇暋 毵れ垬 12/29/2023(25), 06/28/2024(28), 12/31/2024(29) 氚� 鞝滍暅欤� 氩犾姢韺� 02/18/2025(5,911)瓿� 02/20/2025(1,507). 鞝滌稖鞛惖鐢 斓滉芳 3臧滌洈臧勳潣 毵る弰鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚措澕瓿� 氤搓碃頄堨溂氅�, 韺愲Г鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟电� 響滌 歆勳垹鞚� 韽暔頄堨姷雼堧嫟.
Zimmer Biomet signale la cession propos茅e de 7,500 actions ordinaires via Fidelity Brokerage sur le NYSE, pour une valeur marchande totale de $766,708.20, pr茅vue le 08/13/2025. Le d茅p么t indique 198,095,984 actions en circulation et pr茅cise que les titres 脿 vendre ont 茅t茅 acquis par des programmes employ茅s : petits achats ESPP le 12/29/2023 (25), 06/28/2024 (28) et 12/31/2024 (29), et lev茅es de restrictions (vesting) d'actions restreintes le 02/18/2025 (5,911) et le 02/20/2025 (1,507). Le d茅clarant indique Rien 脿 signaler concernant des ventes au cours des trois derniers mois et inclut la d茅claration standard selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Zimmer Biomet meldet einen vorgeschlagenen Verkauf von 7,500 Stammaktien 眉ber Fidelity Brokerage an der NYSE mit einem Gesamtmarktwert von $766,708.20, geplant f眉r den 08/13/2025. Die Einreichung nennt 198,095,984 ausstehende Aktien und weist aus, dass die zu verkaufenden Wertpapiere durch Mitarbeiterprogramme erworben wurden: kleine ESPP-K盲ufe am 12/29/2023 (25), 06/28/2024 (28) und 12/31/2024 (29) sowie Vesting von Restricted Stock am 02/18/2025 (5,911) und 02/20/2025 (1,507). Der Meldende gibt f眉r Verk盲ufe in den letzten drei Monaten Nichts zu melden an und f眉gt die 眉bliche Erkl盲rung hinzu, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does the Zimmer Biomet (ZBH) Form 144 report?
How were the shares to be sold acquired?
Has the filer sold any ZBH securities in the past three months?
Which broker and exchange are identified for the proposed sale?
Does the filing address material nonpublic information or trading plans?
